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Original Investigation | Oncology

Association Between Sex and Immune Checkpoint Inhibitor Outcomes
for Patients With Melanoma
Se Ryeong Jang, MPH; Nikita Nikita, MBBS, MPH; Joshua Banks, MS; Scott W. Keith, PhD; Jennifer M. Johnson, MD, PhD;
Melissa Wilson, MD, PhD; Grace Lu-Yao, MPH, PhD

Abstract

Key Points

IMPORTANCE Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment and
are now standard of care. Although sex is associated with immune function and immune-related
diseases, the interaction between sex and ICIs is understudied.

Question Does the effectiveness of
cancer immunotherapy vary between
female and male patients with advanced
melanoma?

OBJECTIVE To examine whether cancer immunotherapy effectiveness varies between female and

Findings In this population-based

male patients with advanced melanoma treated with either nivolumab plus ipilimumab combination

cohort study that included 1369 patients

therapy or anti–programmed cell death protein 1 (PD-1) therapy (namely, pembrolizumab or

65 years of age or older with advanced

nivolumab).

melanoma, a significant sex difference in
overall mortality was seen among

DESIGN, SETTING, AND PARTICIPANTS The study population consisted of 1369 older adults (aged

patients treated with nivolumab plus

ⱖ65 years) with a record of melanoma diagnosis from January 1, 1991, to December 31, 2015, in the

ipilimumab combination

Surveillance, Epidemiology, and End Results–Medicare linked database. Patients with a diagnosis of

immunotherapy, with women having a

stage III or stage IV melanoma and a claims record showing nivolumab plus ipilimumab combination

2-fold higher mortality risk than their

therapy or anti–PD-1 therapy (ie, pembrolizumab or nivolumab) as their last type of ICI prescribed

male counterparts.

were included in the analyses. Patients were followed up through December 31, 2017, for the overall
survival analysis. Statistical analysis was performed from September 19, 2019, to February 20, 2021.

Meaning This study suggests that the
sex of the patient must be considered
when designing a treatment strategy for

EXPOSURES Sex, last prescribed ICI, and prior use of ipilimumab.

patients with metastatic melanoma to
optimize outcomes.

MAIN OUTCOMES AND MEASURES The primary outcome was overall survival, defined as time
from the index date until death from any cause, with patients censored at the end of the study
(December 31, 2017). Cox proportional hazards regression modeling was used to examine the
association of sex with ICI outcomes while adjusting for prior use of ipilimumab, age at ICI initiation,
Charlson Comorbidity Index, cancer stage at the time of diagnosis, and autoimmune disease

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

diagnosis.
RESULTS Among the 1369 patients in the study (982 men [71.7%]; median age, 75 years [IQR, 69-82
years]), the outcome of nivolumab plus ipilimumab combination therapy depended on sex (Wald
χ2 = 9.48; P = .009 for interaction). The mortality hazard ratio (HR) for women with prior ipilimumab
use receiving combination therapy was 2.06 times (95% CI, 1.28-3.32; P = .003) higher than their
male counterparts. No significant difference was observed between women and men receiving anti–
PD-1 therapy with (HR, 0.97 [95% CI, 0.68-1.38]; P = .85) or without prior ipilimumab use (HR, 0.85
[95% CI, 0.67-1.07]; P = .16). For women with prior ipilimumab use, combination therapy was
associated with 2.82 times higher mortality hazards than anti–PD-1 therapy (95% CI, 1.73-4.60). No
statistically significant difference was seen in mortality risk between anti–PD-1 therapy and
combination therapy for men.
(continued)
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Abstract (continued)

CONCLUSIONS AND RELEVANCE This cohort study suggests that female patients with advanced
melanoma may not benefit as much from combination ICIs as male patients would. Tumor mutation
burden or estrogen level may serve as an important biomarker associated with ICI response in
metastatic melanoma.
JAMA Network Open. 2021;4(12):e2136823. doi:10.1001/jamanetworkopen.2021.36823

Introduction
Immune checkpoint inhibitors (ICIs) are now the mainstay of treatment for advanced melanoma. To
date, the US Food and Drug Administration has approved the following 3 ICIs for the treatment for
advanced melanoma: ipilimumab (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] inhibitor),
pembrolizumab, and nivolumab (programmed cell death protein 1 [PD-1] inhibitors). These ICIs have
improved the prognosis of metastatic melanoma by reversing effector T-cell dysfunction and
exhaustion, thereby reinvigorating antitumor immune response.1-3 Acting at different points in the
T-cell response pathway, the CTLA-4 inhibitor and the PD-1 inhibitor could generate a synergistic
effect when used in combination.4,5 For instance, nivolumab plus ipilimumab resulted in the highest
5-year survival rate (52%) compared with nivolumab alone (44%) and ipilimumab alone (26%) in
the recent update of the phase 2 CheckMate 067 trial.6 However, the combination therapy is
associated with high toxicity, and the overall ICI response rate remains low, at 30% to 40%.1,5,7,8 It is
therefore imperative to identify factors associated with drug responses to optimize ICI strategies.
Biological markers such as sex may serve as an important factor associated with ICI response in
patients with melanoma based on the following observations. First, the incidence of melanoma
varies between women and men by age. Although melanoma is predominantly found in men older
than 50 years of age, female patients make up 60% of patients younger than 50 years with
melanoma.9 The comparatively low incidence of melanoma among postmenopausal women coupled
with the high incidence of melanoma among women in their reproductive years suggests that sex
hormones, such as estrogen, may play a role in the development of melanoma.10 Second, faster
clearance of pathogens and greater vaccine effectiveness are seen in women.11,12 Third, women are
4-fold more susceptible to autoimmune diseases than men.11,12 These observations illustrate that
women mount stronger immunologic responses to foreign and self-antigens and may respond to ICIs
differently than their male counterparts.13
It is uncertain whether the effectiveness of ICI-based immunotherapy treatment of metastatic
melanoma varies by sex. Therefore, we conducted a population-based cohort study to address this
question.

Methods
Study Design and Data Source
This observational cohort study consists of Medicare patients receiving either a PD-1 inhibitor
(nivolumab or pembrolizumab) or nivolumab plus ipilimumab combination therapy for advanced
melanoma. The main data source was Surveillance, Epidemiology, and End Results (SEER)–Medicare
linked data, including patients who received a diagnosis of melanoma between 1991 and 2015.
The SEER-Medicare linked files include clinical data from population-based cancer registries and
health encounter records for those with fee-for-service insurance. As of 2017, the SEER program
covered approximately 35% of the US population, with a 98% case ascertainment rate.14,15 Our
patient cohort represents approximately 60% of Medicare beneficiaries.
The research question, study design, and end points were all prespecified in the research
protocol, as recommended in the Strengthening the Reporting of Observational Studies in
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Epidemiology (STROBE) reporting guidelines.16 The study was approved by the Thomas Jefferson
University institutional review board, which waived the need for obtaining informed patient consent
because the data were deidentified, and conformed to the data user agreement.

Study Population
Patients with a diagnosis of melanoma (International Classification of Diseases, Ninth Revision codes
172.0-172.9; International Statistical Classification of Diseases and Related Health Problems, Tenth
Revision codes C43.0-C43.9) in the SEER registry between January 1, 1991, and December 31, 2015,
were identified. We excluded those who received a diagnosis after death, were enrolled in health
maintenance organizations, or had no Medicare Part A or B coverage during the study period. We
further restricted the patient cohort by including only those who had a claims record of nivolumab
(Healthcare Common Procedure Coding System [HCPCS] code J9299), pembrolizumab (HCPCS
code J9228), or nivolumab plus ipilimumab combination therapy (presence of both HCPCS codes on
the same date). Claims records for pembrolizumab and nivolumab were available from January 1 to
December 29, 2016, while records for ipilimumab prescriptions were available from January 1, 2012,
to December 29, 2016. Given that claims for nivolumab were made starting in 2016 in our data set,
prescriptions for nivolumab plus ipilimumab combination therapy were only available for 2016. The
difference in the availability of claims records for each treatment reflects the US Food and Drug
Administration approval dates for each (ipilimumab, 2011; pembrolizumab and nivolumab, 2014;
nivolumab plus ipilimumab combination, 2015).

Exposure and Outcome Definitions
The main exposure of interest was the last ICI administered. We classified treatment groups by the
last prescription for ICI(s) as captured in Medicare’s claims files (ie, the Outpatient file and the
National Claims History file). We followed up with patients from the first prescription date for the last
ICI captured in their claims file until death or last date of vital status available.
Our data indicated that 30.0% (362 of 1204) of patients receiving anti–PD-1 therapy had prior
ipilimumab use, whereas 100% of patients receiving combination therapy had prior ipilimumab use.
To control for the significant imbalance in history of ipilimumab use, we further classified the patient
cohort into the following subgroups: anti–PD-1 therapy without prior ipilimumab use, anti–PD-1
therapy with prior ipilimumab use, and combination therapy with prior ipilimumab use (Figure 1).
We used the Patient Entitlement and Diagnosis Summary File from the SEER Program and
Medicare claims to identify the following variables: sex, age at diagnosis and at index time (initiation
date of the last type of ICI administered), year of diagnosis, SEER region, cancer stage at diagnosis,
autoimmune disease diagnosis, tumor sequence, and history of radiotherapy or surgery. Given that
SEER cancer registries and Medicare claims are completed based on data collected in clinical settings,
demographic information, such as race and sex, reflect the information provided by the patient.17
We used the 2015 SEER-Medicare Census Zip Code file to derive quartiles of zip code–level median
per capita income and percentage of residents who were high school graduates. The modification by
Warren et al14 of the Charlson Comorbidity Index (CCI) was used to quantify severity of preexisting

Figure 1. Breakdown of Patient Cohort
Subgroup classification
Patients receiving anti–PD-1 therapy
with prior use of ipilimumab (30%)

Prior use of ipilimumab
Pembrolizumab or nivolumab
(anti-PD-1)

Patients receiving anti–PD-1 therapy
without prior use of ipilimumab (70%)
Patients receiving nivolumab
plus ipilimumab combination therapy
with prior use of ipilimumab (100%)
January 1,
2012

Nivolumab plus
ipilimumab

Prior use of ipilimumab

January 1,
2016
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comorbidities. The primary outcome was overall survival, defined as time from the index date until
death from any cause, with patients censored at the end of the study (December 31, 2017).

Statistical Analysis
Statistical analysis was performed from September 9, 2019, to February 20, 2021. The Kaplan-Meier
method was used to compare overall survival between female and male patients. Differences in
time-to-event outcomes between sexes were evaluated using the log-rank test. Effect modification
by sex was tested using a Cox proportional hazards regression model with an interaction term for
each subgroup and sex. Sex differences in mortality were examined using Cox proportional hazards
regression models, which adjusted for age at index date, CCI, cancer stage at the time of diagnosis,
and autoimmune disease diagnosis. All statistical analyses were 2-sided and performed at the 5%
significance level using SAS, version 9.4 statistical software (SAS Institute Inc). To evaluate the
effectiveness of each treatment in comparison with another among female and male patients, we set
“anti–PD-1 with prior ipilimumab use” as the reference group to calculate the hazard ratio (HR) for
the other 2 treatment subgroups within each sex.

Results
Patients
In total, 1369 patients (982 men [71.7%] and 387 women [28.3%]; median age, 75 years [IQR, 69-82
years]; 165 [12.1%] with ⱖ1 autoimmune diagnosis) with a diagnosis of melanoma met study inclusion
criteria (Table 1). A total of 1204 patients (87.9%) were receiving anti–PD-1 therapy, while the
remaining 165 patients (12.1%) were receiving combination therapy.
Female and male patients were similar across all clinical and demographic characteristics except
in the prevalence of autoimmune disease. A significantly higher proportion of women than men (67
of 387 [17.3%] vs 98 of 982 [10.0%]) had a diagnosis of autoimmune disease (Table 1).

Mortality by Sex
The distribution of death was comparable between women and men among those patients receiving
anti–PD-1 therapy, regardless of their prior use of ipilimumab (prior use of ipilimumab: women, 45 of
113 [39.8%] and men, 102 of 249 [41.0%]; and no prior use of ipilimumab: women, 95 of 234 [40.6%]
and men, 274 of 608 [45.1%]) (eTable in the Supplement). Conversely, there was imbalance in the
distribution of death between female and male patients receiving the nivolumab plus ipilimumab
combination therapy (26 of 40 [65.0%] vs 50 of 125 [40.0%]).
Patients were followed up for up to 24 months. Median survival was not reached for either sex
in the entire patient cohort, and there was not a significant difference in survival between men and
women (eFigure 1 in the Supplement). When survival analyses were performed for the 3 predefined
subgroups, median survival was reached only for female patients receiving combination therapy
(10.2 months; 95% CI, 4.6-23.9 months) (Figure 2). More than 50% of patients receiving anti–PD-1
therapy survived by the end of the study period, regardless of their prior ipilimumab use (no
ipilimumab history, 473 of 842 [56.2%]; and ipilimumab history, 215 of 362 [59.4%]). No significant
difference in survival was seen between male and female patients receiving anti–PD-1 therapy
(eFigures 2 and 3 in the Supplement).
There was evidence of effect modification by sex among patients treated with ICIs. The
interaction term between sex and the subgroup classification, which accounted for both the last ICI
the patient received and their prior ipilimumab use, was significant (Wald χ2 = 9.48; P = .009).
Table 2 shows that, for women with prior ipilimumab use, combination therapy was associated with
2.82 times higher hazard of mortality (95% CI, 1.73-4.60) than anti–PD-1 therapy. On the other hand,
no statistically significant difference was seen in mortality hazards between anti–PD-1 therapy and
combination therapy for men, regardless of prior ipilimumab use. Furthermore, Table 3 shows that
women receiving combination therapy had 2.06 times higher hazard (95% CI, 1.28-3.32; P = .003) of
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overall mortality compared with their male counterparts, after adjusting for age at index date, CCI,
cancer stage, and autoimmune disease diagnosis. No statistically significant difference was observed
between women and men receiving anti–PD-1 therapy with (HR, 0.97 [95% CI, 0.68-1.38]; P = .85)
or without prior ipilimumab use (HR, 0.85 [95% CI, 0.67-1.07]; P = .16).

Discussion
This population-based cohort study showed that female sex was associated with a 2-fold increased
hazard of mortality compared with male sex among those receiving nivolumab plus ipilimumab

Table 1. Demographic and Clinical Characteristics of Patients With Advanced Melanoma
Patients, No. (%)
Characteristic

Female (n = 387)

Male (n = 982)

Anti–PD-1 therapy

347 (89.7)

857 (87.3)

Nivolumab plus ipilimumab combination therapy

40 (10.3)

125 (12.7)

Yes

153 (39.5)

374 (38.1)

No

234 (60.5)

608 (61.9)

<70

109 (28.2)

276 (28.1)

70-79

151 (39.0)

407 (41.4)

≥80

127 (32.8)

299 (30.4)

1991-2000

28 (7.2)

80 (8.1)

2001-2005

47 (12.1)

132 (13.4)

2006-2010

96 (24.8)

236 (24.0)

2011-2015

216 (55.8)

534 (54.4)

0

320 (82.7)

884 (90.0)

≥1

67 (17.3)

98 (10.0)

Immune checkpoint inhibitors

History of ipilimumab

Age at index time
(administration of the immunotherapy), y

Year of diagnosis

Autoimmune disease diagnosis

Cancer history
Melanoma only

193 (49.9)

449 (45.7)

History of other primary cancer

194 (50.1)

533 (54.3)

0

276 (71.3)

685 (69.8)

≥1

111 (28.7)

297 (30.2)

0-II or unknown

284 (73.4)

700 (71.3)

III

67 (17.3)

196 (20.0)

IV

36 (9.3)

86 (8.8)

No radiotherapy or surgery

338 (87.3)

857 (87.3)

Radiotherapy and surgery (once each)

49 (12.7)

125 (12.7)

Northeast

82 (21.2)

190 (19.3)

South

81 (20.9)

203 (20.7)

North central

26 (6.7)

80 (8.1)

West

198 (51.2)

509 (51.8)

Per capita income, $

31 130 (23 773-42 575)

31 180.5 (24 464-41 622)

High school graduate, %

23.9 (16.6-31.2)

23.8 (16.4-31.3)

Charlson Comorbidity Index

Cancer stage at diagnosis

History of radiotherapy

SEER region

Zip code–level, median (IQR)
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combination therapy. In addition, combination therapy was associated with 2.82 times higher hazard
of mortality than anti–PD-1 therapy for women with prior ipilimumab use. These novel findings
suggest that, for women with a prior history of ipilimumab, treatment with anti–PD-1 therapy may be
preferable to combination therapy, whereas for men, it is unclear which treatment is better.
To our knowledge, analyses of the association of sex with the effectiveness of ICIs in advanced
melanoma have been conducted only using clinical trial data. Clinical trials are at risk for having
nongeneralizable results owing to referral bias and strict inclusion criteria. By using the SEERMedicare linked data, we included older patients and those with autoimmune diseases and
minimized those biases. By design, this population-based cohort study ensured that the patient
cohort was representative of patients with advanced melanoma in real life.

Potential Mechanism of Action
The sex dimorphism seen in ICI response among the patients receiving combination therapy may be
explained by the sex-associated molecular difference in tumors, particularly in tumor mutation
burden (TMB) and neoantigens. Immune checkpoint inhibitors are designed to elicit T-cell responses
directed at immunogenic neoantigens. These neoantigens exist owing to the mutations in the coding
region of the tumor genome.18 Therefore, if the TMB is high and, in turn, if antigens are produced in
a large quantity, the effectiveness of the immunotherapy could be optimized.19 Studies evaluating
The Cancer Genome Atlas cancers identified significant sex-mutation differential in melanoma, with a

Figure 2. Overall Survival for Patients Receiving Nivolumab Plus Ipilimumab Combination Therapy, by Sex
1.0

Survival probability, %

0.8
Male

0.6

0.4
Female
0.2

0
0

4

8

12

16

20

85
17

51
14

25

Time, mo
No. at risk
Male
Female

125
40

100
28

88
23

Median survival was reached for female patients
receiving combination therapy (10.2 months [95% CI,
4.6-23.9 months]), while more than 50% of male
patients receiving combination therapy survived by
the end of the study period (75 of 125 [60.0%]).

Table 2. Multivariable Cox Proportional Hazard Regression Analysis of Overall Mortality Hazard Ratio
Hazard ratio (95% CI)
Subgroup

Female patients

Male patients

With prior ipilimumab use

1 [Reference for other female
subgroups]

1 [Reference for other male
subgroups]

Without prior ipilimumab use

1.06 (0.74-1.51)

1.21 (0.96-1.53)

2.82 (1.73-4.60)

1.32 (0.94-1.87)

Anti–PD-1

Combination therapy with prior ipilimumab use

Abbreviation: PD-1, programmed cell death protein 1.

Table 3. Multivariable Cox Proportional Hazard Regression Analysis of Overall Mortality Hazard Ratio
Subgroup

Female vs male patients, HR (95% CI)

P value

With ipilimumab history

0.97 (0.68-1.38)

.85

Without ipilimumab history

0.85 (0.67-1.07)

.16

2.06 (1.28-3.32)

.003

Anti–PD-1 therapy

Combination therapy with ipilimumab history
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lower TMB in female patients.20,21 Furthermore, Ye et al21 demonstrated a survival disadvantage in
female patients with melanoma receiving ICIs, drawing an association between TMB and ICI
effectiveness. A recent report showed that the tumor-expressed antigens in women are also less
likely to be presented to the immune system by the major histocompatibility complex.22 Stronger
immune selection during tumorigenesis in women is posited as the reason why immunogenecity of
the remaining tumor cells tends to be low.23 Both the low level of TMB and immunologically invisible
neoantigens may explain the reduced association of ICI treatment with outcomes among women
receiving combination therapy in our study.
In addition to the tumor mutations, the change in the estrogen signaling pathway with aging
may also be associated with the varying levels of ICI treatment response observed between women
and men with melanoma who are receiving combination therapy. The expression of estrogen
receptor (ER)–β is directly related to the endogenous estrogen level.24 Studies demonstrated that
when ER-β expression decreases owing to the reduced production of estrogen, cellular proliferation
becomes uncontrolled, leading to metastasis.24,25 The decrease in ER-β expression and the
consequent disturbance in the balance between ER-α and ER-β are thought to be associated with
resistance to the ER antagonist tamoxifen in breast cancer cells.6,26,27 Given that the patient
population comprised Medicare beneficiaries, all women were in their postmenopausal period and
were likely to have experienced a decrease in ER-β expression. Although evaluation of the ER-β
expression level between postmenopausal women and older men is warranted, we posit that
unfavorable mortality among women receiving combination therapy may be due to this change in the
estrogen signaling pathway.
It is unknown why sex-specific survival was seen in the combination therapy group but not in
the anti–PD-1 therapy group. Although the association of sex with immunotherapy effectiveness has
been examined in multiple meta-analyses, none has tested this hypothesis specifically for patients
with advanced melanoma receiving anti–PD-1 therapy or combination therapy, to our knowledge. The
meta-analyses either combined multiple types of patients with cancer to investigate the sex
differential in survival by treatment group,28,29 or vice versa.21,29 Therefore, it is impossible to assess
the external validity of our study results. We speculate that the difference in the mechanism between
PD-1 inhibitors and CTLA-4 inhibitors may have resulted in the difference in the association of sex
with outcomes that we see between the 2 immunotherapy groups. Programmed cell death protein 1
inhibitors and CTLA-4 inhibitors work at different points in T-cell regulation, and they may interact
differently with sex-specific biomarkers. Future studies are warranted to test this hypothesis.

Clinical Implications
The effect modification by sex among patients treated with ICIs is not a phenomenon specific to
patients with melanoma receiving combination therapy. The meta-analysis by Conforti et al28 of 20
phase 2 and phase 3 trials among patients with multiple advanced cancers, mostly including
melanoma and non–small-cell lung cancer (NSCLC), demonstrated a statistically significant difference
in effectiveness between female and male patients treated with a CTLA-4 inhibitor and a PD-1
inhibitor. For female patients receiving ICI treatment, the pooled mortality HR was 0.86 (95% CI,
0.79-0.93), while for male patients, the pooled mortality HR was 0.72 (95% CI, 0.65-0.79), and the
difference was significant (P = .002). Female patients with NSCLC had a significant overall survival
advantage associated with PD-1 inhibitor or programmed death-ligand 1 inhibitor treatment
combined with chemotherapy compared with treatment with chemotherapy alone, suggesting that
an ICI combined with chemotherapy may bring out the optimal outcome for female patients with
NSCLC.28 A recent, real-world data analysis by Hadash-Bengad et al30 shares the same suggestion for
metastatic melanoma treatment. In their analysis, the authors observed a significant improvement
in progression-free survival and clinically meaningful improvement in overall survival among patients
who were treated with chemotherapy after ICI-based immunotherapy. These findings illustrate that
treating metastatic melanoma with chemotherapy combined with ICIs may enhance the immune
response and optimize the immunotherapy treatment, particularly for women.
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Despite the accumulating evidence of the potential role played by sex in drug effectiveness
owing to the biological differences between men and women, the effectiveness of new therapeutic
approaches is rarely examined by sex.31,32 This lack of attention on the association of sex with the
effectiveness of ICI-based immunotherapy may have significant negative consequences, especially
because these treatments are associated with high toxicity and high treatment cost. For future trials,
it would be crucial to examine effect modification by sex.

Limitations
This analysis has several limitations. First, in the SEER-Medicare data set, we did not have access to
clinical data that would have provided patients’ cancer stage at the time of ICI administration, cause
of mortality, and regimen dose. We assumed that the patients in our analytic cohort had progressed
to stage III or IV melanoma by the index date, given that these therapies were approved for those
with unresectable (stage III) or metastatic (stage IV) melanoma, and were receiving the same dose.
Second, our study included 165 patients receiving combination therapy, with only 40 of them being
women (Table 1). This relatively small sample size may have introduced selection bias. Nonetheless,
we observed that the mortality pattern in treatment groups followed the pattern seen in clinical
trials, with patients receiving combination therapy having higher mortality than those receiving anti–
PD-1 therapy (eFigure 3 in the Supplement). Third, an observational study is subject to residual
confounding owing to the lack of randomization. Given that combination therapy is associated with
higher toxicity than monotherapy, physicians are more likely to prescribe combination therapy to
younger and/or healthier patients. Although controlling for patient’s age, CCI, cancer stage, and
autoimmune disease diagnosis may have helped reduce selection bias, confounders that were not
observed in our analyses may have been associated with immunotherapy outcomes. Fourth, the
potential residual effects of prior treatments may have been a factor associated with overall survival.
There were 26 of 165 patients in the combination therapy group (15.8%) who were receiving anti–
PD-1 therapy prior to switching to combination therapy. Recent reports demonstrate that
approximately one-third of the patients who failed to respond to anti–PD-1 monotherapy responded
to combination therapy. Patients who were refractory to ipilimumab were also observed to respond
to combination therapy in clinical settings.33-35 Therefore, we treated the patients receiving
combination therapy who switched from an anti–PD-1 therapy the same as those who switched from
ipilimumab. However, there are still many uncertainties around the mechanism of action, and this
group should be investigated separately in a study with a larger sample size.
Although literature provides strong evidence that immunotherapy may not be as effective for
female patients with melanoma as it is for their male counterparts owing to biological differences, we
cannot completely rule out the possibility that the differences in outcomes may be due to differences
in behavioral patterns (eg, smoking, outdoor activities, and health care resource use). It would be
imperative to replicate this study with a larger patient population, including younger cohorts to
examine whether genetic and hormonal factors play a role in ICI response. Furthermore, it is not
possible for us to understand why the sex differential was observed only among patients receiving
combination therapy and not among those receiving anti–PD-1 therapy. Future research using clinical
and molecular-level data is warranted to further understand the mortality pattern observed in
this study.

Conclusions
In this population-based cohort study, we observed that female patients with advanced melanoma
treated with nivolumab plus ipilimumab combination therapy had an overall mortality risk 2 times
higher than their male counterparts after adjusting for known confounding variables. Further
research is warranted to validate our findings, to explore potential biological mechanisms, and to
design optimal treatment strategies tailored to each patient.
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